|
US 12,281,146 B2 |
|
| Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| Colette Song, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE) |
| Assigned to Immatics Biotechnologies GmbH, Tübingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Aug. 12, 2022, as Appl. No. 17/819,470. |
| Application 17/819,470 is a continuation of application No. 17/871,724, filed on Jul. 22, 2022. |
| Application 17/871,724 is a continuation of application No. 17/860,600, filed on Jul. 8, 2022. |
| Application 17/860,600 is a continuation of application No. 17/371,755, filed on Jul. 9, 2021, granted, now 11,866,473. |
| Application 17/371,755 is a continuation of application No. 17/227,885, filed on Apr. 12, 2021, granted, now 11,168,122, issued on Nov. 9, 2021. |
| Application 17/227,885 is a continuation of application No. 16/913,788, filed on Jun. 26, 2020, granted, now 11,001,616, issued on May 11, 2021. |
| Application 16/913,788 is a continuation of application No. 16/026,707, filed on Jul. 3, 2018, granted, now 10,800,823, issued on Oct. 13, 2020. |
| Claims priority of provisional application 62/529,758, filed on Jul. 7, 2017. |
| Claims priority of application No. 102017115301.2 (DE), filed on Jul. 7, 2017. |
| Prior Publication US 2023/0287069 A1, Sep. 14, 2023 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); C12N 15/115 (2010.01); G01N 33/574 (2006.01) |